A purified form of cannabidiol (CBD) is now available in the U.S. to treat a pair of rare, severe forms of epilepsy for patients two years of age and older, representing the first U.S. Food and Drug Administration (FDA)-approved plant-derived CBD medicine available in the U.S.
GW Pharmaceuticals has made Epidolex available as an oral solution to treat Lennox-Gastaut syndrome (LGS) or Dravet syndrome that usually develops in children between three and five.
The drug was first approved by the FDA in June 2018 as a scheduled I drug. Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. It was reclassified as a Schedule V substance—a drug with low potential for abuse—by the U.S. Department of Justice in September, a move that opened up its use significantly in the U.S.
“We are delighted to announce that EPIDIOLEX is now